VIKTORIA-1:Gedatolisib联合氟维司群±哌柏西利治疗HR+/HER2-/PIK3CA野生型晚期乳腺癌
VIKTORIA-1是一项III期随机试验,纳入392例CDK4/6抑制剂和芳香化酶抑制剂治疗后进展的HR+/HER2-/PIK3CA野生型晚期乳腺癌患者,按1:1:1随机接受Gedatolisib三联(Gedatolisib+哌柏西利+氟维司群)、Gedatolisib双联(Gedatolisib+氟维司群)或氟维司群单药治疗。主要终点为盲法独立中心评估的无进展生存期(PFS)。结果显示,三联组中位PFS为9.3个月,双联组为7.4个月,单药组为2.0个月;
要点
- Gedatolisib三联较氟维司群单药显著延长PFS(9.3 vs 2.0个月,HR 0.24)。
- Gedatolisib双联较氟维司群单药亦显著改善PFS(7.4 vs 2.0个月,HR 0.33)。
- 三联组≥3级中性粒细胞减少发生率为62.3%,双联组为0.8%。
核心结论
- 在HR+/HER2-/PIK3CA野生型晚期乳腺癌患者中,Gedatolisib联合氟维司群(±哌柏西利)较氟维司群单药显著降低疾病进展或死亡风险。
研究设计与样本
- III期随机试验(VIKTORIA-1,NCT05501886),纳入392例CDK4/6抑制剂和芳香化酶抑制剂治疗后进展的HR+/HER2-/PIK3CA野生型晚期乳腺癌患者,按1:1:1随机分配。
- 主要终点为盲法独立中心评估的PFS,分别比较Gedatolisib三联 vs 氟维司群和Gedatolisib双联 vs 氟维司群。
主要发现
- 三联组和双联组≥3级治疗相关不良事件分别包括中性粒细胞减少(62.3% vs 0.8%)、口腔炎(19.2% vs 12.3%)、皮疹(4.6% vs 5.4%)、高血糖(2.3% vs 2.3%)和腹泻(1.5% vs 0.8%)。
- 因治疗相关不良事件导致研究治疗终止的比例在三联组为2.3%,双联组为3.1%。
临床怎么用
- 对于CDK4/6抑制剂和芳香化酶抑制剂治疗后进展的HR+/HER2-/PIK3CA野生型晚期乳腺癌患者,Gedatolisib联合氟维司群(联合或不联合哌柏西利)可作为新的治疗选择。
- 含哌柏西利的三联方案需关注中性粒细胞减少等血液学毒性,双联方案骨髓抑制较轻但口腔炎等非血液学毒性需管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Gedatolisib potently targets all four class I PI3K isoforms and mTORC1 and mTORC2 to comprehensively block the PI3K/AKT/mTOR pathway and has shown compelling activity in early clinical trials with palbociclib and fulvestrant. METHODS: This phase III randomized trial (VIKTORIA-1; ClinicalTrials.gov identifier: NCT05501886) evaluated the efficacy of gedatolisib-based therapy, comparing gedatolisib, palbociclib, and fulvestrant (gedatolisib triplet) and gedatolisib plus fulvestrant (gedatolisib doublet) with fulvestrant monotherapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HER2-), PIK3CA wild-type (WT) advanced breast cancer. Eligible patients had disease progression during or after CDK4/6 inhibitor and aromatase inhibitor treatment. Comparison of progression-free survival as assessed by blinded independent central review for gedatolisib triplet versus fulvestrant and gedatolisib doublet versus fulvestrant was the primary objective. RESULTS: A total of 392 patients were randomly assigned 1:1:1. The median study follow-up was 10.1 months. The median progression-free survival was 9.3 months in the gedatolisib-triplet group, 2.0 months in the fulvestrant group (hazard ratio [HR] for progression or death, 0.24 [95% CI, 0.17 to 0.35]; P < .001), and 7.4 months in the gedatolisib-doublet group (HR, 0.33 [95% CI, 0.24 to 0.48]; P < .001 v fulvestrant). Grade ≥3 treatment-related adverse events (TRAEs) reported in the gedatolisib-triplet and gedatolisib-doublet groups, respectively, included neutropenia (62.3%, 0.8%), stomatitis (19.2%, 12.3%), rash (4.6%, 5.4%), hyperglycemia (2.3%, 2.3%), and diarrhea (1.5%, 0.8%). Study treatment discontinuation because of TRAEs was reported in 2.3% (triplet) and 3.1% (doublet) of patients. CONCLUSION: The addition of gedatolisib to fulvestrant, with or without palbociclib, significantly reduced the risk of disease progression or death in patients with hormone receptor-positive/HER2-, PIK3CA WT advanced breast cancer.
引用
- Hurvitz SA, Layman RM, Curigliano G, et al. VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer. J Clin Oncol. 2026. PMID: 41802242. doi:10.1200/JCO-25-02643
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。